1. Kongkrongtong, T., et al. "Reprogramming signal transduction through a designer receptor tyrosine kinase." Commun. Biol. 4, 752 (2021).2. Nakajima, K., et al. "Tailoring minimal synthetic receptors to reconstitute signaling properties through multiple tyrosine motifs." Biochem. Biophys. Res. Commun. 566, 148-154 (2021).3. Kashima, D., et al. "Evolution of KIPPIS as a versatile platform for evaluating intracellularly functional peptide aptamers." Sci. Rep. 11, 11758 (2021).4. Kashima, D., et al. "A Novel Cell-Based Intracellular Protein-Protein Interaction Detection Platform (SOLIS) for Multimodality Screening." ACS Synth. Biol. 10, 990-999 (2021).5. Tsukamoto, T., et al. "Chimeric G-CSF receptor-mediated STAT3 activation contributes to efficient induction of cardiomyocytes from mouse induced pluripotent stem cells." Biotechnol. J. 15, 1900052 (2020).6. Eguchi, A., et al. "An epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout." Biotechnol. Bioeng. 116, 1742-1751 (2019).7. Nguyen, T. D., et al. "A suicide switch directly eliminates intracellular scFv oligomers in the cytoplasm of mammalian cells." Biotechnol. J. 14, 1800350 (2019).8. Ishizuka, S., et al. "Designing Motif-Engineered Receptors To Elucidate Signaling Molecules Important for Proliferation of Hematopoietic Stem Cells." ACS Synth. Biol. 7, 1709-1714 (2018).9. Saka, K., et al. "Dissection of signaling events downstream of the c-Mpl receptor in murine hematopoietic stem cells via motif-engineered chimeric receptors." Stem Cell Rev. Rep. 14, 101–109 (2018).□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□Guest Professor Masahiro KAWAHARA 072-641-8043 招へい教授 河原 正浩 https://www.nibiohn.go.jp/cellvaccine/m-kawahara@nibiohn.go.jp招へい教授 河原 正浩1）キメラ受容体による細胞運命制御系の開発2）細胞運命シグナルを利用した創薬プラットフォームの開発3）細胞内シグナル伝達のカスタム設計□□□□□□□□□□□□□□□□□Cell Vaccine
元のページ ../index.html#48